ANI Pharmaceuticals, Inc.ANIPNASDAQ
Loading
Net Income Growth Under PressureDecelerating
Percentile Rank44
3Y CAGR-35.0%
Year-over-Year Change
Year-over-year net income growth rate
3Y CAGR
-35.0%/yr
Quarterly compound
Percentile
P44
Within normal range
vs 3Y Ago
0.3x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 13.91% |
| Q3 2025 | 182.30% |
| Q2 2025 | -45.48% |
| Q1 2025 | 252.60% |
| Q4 2024 | 57.48% |
| Q3 2024 | -956.67% |
| Q2 2024 | -112.56% |
| Q1 2024 | 1476.36% |
| Q4 2023 | -88.38% |
| Q3 2023 | 59.17% |
| Q2 2023 | 333.98% |
| Q1 2023 | 133.91% |
| Q4 2022 | 50.66% |
| Q3 2022 | 42.37% |
| Q2 2022 | 25.87% |
| Q1 2022 | 16.60% |
| Q4 2021 | -442.75% |
| Q3 2021 | 68.47% |
| Q2 2021 | -16502.33% |
| Q1 2021 | 102.37% |
| Q4 2020 | -937.56% |
| Q3 2020 | 103.52% |
| Q2 2020 | -75.95% |
| Q1 2020 | -45.01% |
| Q4 2019 | -226.17% |
| Q3 2019 | -40.85% |
| Q2 2019 | 1372.27% |
| Q1 2019 | -91.82% |
| Q4 2018 | 7.84% |
| Q3 2018 | 81.38% |
| Q2 2018 | 22.89% |
| Q1 2018 | 123.23% |
| Q4 2017 | -305.53% |
| Q3 2017 | 76.06% |
| Q2 2017 | 133.22% |
| Q1 2017 | 205.65% |
| Q4 2016 | -142.76% |
| Q3 2016 | 126.14% |
| Q2 2016 | -16.58% |
| Q1 2016 | -53.39% |